Drug intelligence / Profile preview

Spexin

Development stage: Unknown
Modality: Small Molecules, Peptides
Administration: Oral, Intracerebroventricular, Intranasal

Overview

Spexin, also known as Neuropeptide Q, is a novel peptide involved in various physiological processes. It acts as a **GAL2/3 agonist** and is implicated in the regulation of **obesity**, **energy homeostasis**, **appetite control**, and **metabolic disorders**. Additionally, there is a cephalosporin antibiotic named Spexin, used to treat bacterial infections.

Brand names: Spexin 250 MG Tablet DTSpexin250 MG Tablet DTSpexin-250 MG Tablet DT
Other names: Neuropeptide Q

Targets

GALR3 (Galanin receptor 3)GALR2 (Galanin receptor 2)

Beyond the preview

Go deeper on Spexin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spexin.

Explore the full profile